Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agilon Health (AGL) Cash & Current Investments (2020 - 2025)

Agilon Health's Cash & Current Investments history spans 6 years, with the latest figure at $285.1 million for Q4 2025.

  • For Q4 2025, Cash & Current Investments fell 28.71% year-over-year to $285.1 million; the TTM value through Dec 2025 reached $285.1 million, down 28.71%, while the annual FY2025 figure was $285.1 million, 28.71% down from the prior year.
  • Cash & Current Investments reached $285.1 million in Q4 2025 per AGL's latest filing, down from $310.9 million in the prior quarter.
  • In the past five years, Cash & Current Investments ranged from a high of $1.1 billion in Q2 2021 to a low of $105.3 million in Q1 2021.
  • Average Cash & Current Investments over 5 years is $625.1 million, with a median of $526.3 million recorded in 2023.
  • Peak YoY movement for Cash & Current Investments: surged 873.86% in 2021, then crashed 48.69% in 2024.
  • A 5-year view of Cash & Current Investments shows it stood at $1.0 billion in 2021, then decreased by 15.66% to $877.2 million in 2022, then crashed by 44.33% to $488.3 million in 2023, then decreased by 18.1% to $400.0 million in 2024, then dropped by 28.71% to $285.1 million in 2025.
  • Per Business Quant, the three most recent readings for AGL's Cash & Current Investments are $285.1 million (Q4 2025), $310.9 million (Q3 2025), and $327.0 million (Q2 2025).